Search Results - "Doshi, Bhavya S"

Novel approaches to hemophilia therapy: successes and challenges by Arruda, Valder R., Doshi, Bhavya S., Samelson-Jones, Benjamin J.

“…New therapies for hemophilia A and hemophilia B will likely continue to change clinical practice. Ranging from extended half-life to nonfactor products and…”
Get full text

AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life by Doshi, Bhavya S., Samelson-Jones, Benjamin J., Nichols, Timothy C., Merricks, Elizabeth P., Siner, Joshua I., French, Robert A., Lee, Ben J., Arruda, Valder R., Callan, Mary Beth

“…The hemophilias are the most common severe inherited bleeding disorders and are caused by deficiency of clotting factor (F) VIII (hemophilia A) or FIX…”
Get full text

Emerging therapies for hemophilia: controversies and unanswered questions by Arruda, Valder R, Doshi, Bhavya S, Samelson-Jones, Benjamin J

“…Several new therapies for hemophilia have emerged in recent years. These strategies range from extended half-life factor replacement products and non-factor…”
Get full text

Analysis of vector genome integrations in multicentric lymphoma after AAV gene therapy in a severe hemophilia A dog by Van Gorder, Lucas, Doshi, Bhavya S., Willis, Elinor, Nichols, Timothy C., Cook, Emma, Everett, John K., Merricks, Elizabeth P., Arruda, Valder R., Bushman, Frederic D., Callan, Mary Beth, Samelson-Jones, Benjamin J.

“…Adeno-associated viral (AAV) vectors have traditionally been viewed as predominantly nonintegrating, with limited concerns for oncogenesis. However,…”
Get full text

Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition by Doshi, Bhavya S, Gangadharan, Bagirath, Doering, Christopher B, Meeks, Shannon L

“…Development of inhibitory antibodies to coagulation factor VIII (fVIII) is the primary obstacle to the treatment of hemophilia A in the developed world. This…”
Get full text

RNAing toward a new therapy for hemophilia by Doshi, Bhavya S., Sidonio, Robert F.

Get full text

Coagulation factor VIII: biological basis of emerging hemophilia A therapies by Samelson-Jones, Benjamin J., Doshi, Bhavya S., George, Lindsey A.

“…[Display omitted] Coagulation factor VIII (FVIII) is essential for hemostasis. After activation, it combines with activated FIX (FIXa) on anionic membranes to…”
Get full text

Recurrence of a high‐titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis by Doshi, Bhavya S., Witmer, Char M.

Get full text

Gene therapy for hemophilia: what does the future hold? by Doshi, Bhavya S., Arruda, Valder R.

“…Recent phase I/II adeno-associated viral vector-mediated gene therapy clinical trials have reported remarkable success in ameliorating disease phenotype in…”
Get full text

Combined anti‐CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors by Doshi, Bhavya S., Raffini, Leslie J., George, Lindsey A.

“…Background Hemophilia A (HA) inhibitor patients that fail traditional immune tolerance induction (ITI) have increased morbidity and mortality. Preclinical…”
Get full text

Gene therapy for hemophilia: Progress to date and challenges moving forward by Gollomp, Kandace L., Doshi, Bhavya S., Arruda, Valder R.

“…Over the past decades hemophilia has been transformed from a debilitating disease to a manageable condition. However, the current treatment options are…”
Get full text

Hemolysis After Medication Exposure in Pediatric Patients With G6PD Deficiency by Doshi, Bhavya S., Kamdar, Aditi, Lambert, Michele P., Obstfeld, Amrom E.

“…Hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency varies by mutation status and the oxidative stressor. Although classified by percent of…”
Get full text

Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab by Lee, Kyumin, Chau, Julia Q., Suber, Yani B., Sternberg, Anna R., Pishko, Allyson M., George, Lindsey A., Bhoj, Vijay G., Doshi, Bhavya S., Samelson-Jones, Benjamin J.

“…Emicizumab improves the procoagulant activity of select loss-of-function factor IX (FIX) variants with likely dysfunctional assembly of the intrinsic Xase…”
Get full text

Gene Therapy for Hemophilia: Facts and Quandaries in the 21st Century by Arruda, Valder R, Doshi, Bhavya S

“…Therapy for hemophilia has evolved in the last 40 years from plasma-based concentrates to recombinant proteins and, more recently, to non-factor therapeutics…”
Get full text

Diagnosis and Management of Pediatric Venous Thromboembolism: New Therapies on the Horizon by Doshi, Bhavya S., Ellison, Angela M.

“…The incidence of venous thromboembolism (VTE) is increasing in pediatric patients. Prompt recognition and evaluation of VTE in young patients could prevent…”
Get full text

B cell-activating factor modulates the factor VIII immune response in hemophilia A by Doshi, Bhavya S, Rana, Jyoti, Castaman, Giancarlo, Shaheen, Mostafa A, Kaczmarek, Radoslaw, Butterfield, John Ss, Meeks, Shannon L, Leissinger, Cindy, Biswas, Moanaro, Arruda, Valder R

“…Inhibitors of factor VIII (FVIII) remain the most challenging complication of FVIII protein replacement therapy in hemophilia A (HA). Understanding the…”
Get full text

Coagulation factor VIII regulates von Willebrand factor homeostasis invivo by Cao, Wenjing, Trask, Aria R, Bignotti, Antonia I, George, Lindsey A, Doshi, Bhavya S, Sabatino, Denise E, Yada, Noritaka, Zheng, Liang, Camire, Rodney M, Zheng, X Long

“…Coagulation factor VIII (FVIII) and von Willebrand factor (VWF) circulate as a noncovalent complex, but each has its distinct functions. Binding of FVIII to…”
Get full text

Utility of repeat testing in the evaluation for von Willebrand disease in pediatric patients by Doshi, Bhavya S., Rogers, Rachel S., Whitworth, Hilary B., Stabnick, Emily A., Britton, Jessica, Butler, Regina B., Obstfeld, Amrom E., Witmer, Char M.

“…Background Von Willebrand disease (VWD) is the most common inherited bleeding disorder and is caused by quantitative and qualitative defects in von Willebrand…”
Get full text

A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function by Meeks, Shannon L., Cox, Courtney L., Healey, John F., Parker, Ernest T., Doshi, Bhavya S., Gangadharan, Bagirath, Barrow, Rachel T., Lollar, Pete

“…A main complication of treatment of patients with hemophilia A is the development of anti–factor VIII (fVIII) antibodies. The immunogenicity of fVIII…”
Get full text

Iliopsoas hematoma in a patient with sickle cell disease by Zielonka, Benjamin, Cohen, Alan R., Smith‐Whitley, Kim, Doshi, Bhavya S.

“…Although musculoskeletal pain in patients with sickle cell disease (SCD) is most frequently the result of vaso‐occlusive episodes, clinicians often consider…”
Get full text